Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.74 USD | +0.49% |
|
+7.43% | +0.68% |
03:31pm | Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation | MT |
18/06 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.68% | 2.61B | |
+25.20% | 46.56B | |
+45.38% | 41.67B | |
+0.27% | 41.16B | |
+33.67% | 32.4B | |
+20.80% | 28.18B | |
-6.35% | 28.1B | |
+49.19% | 14.52B | |
+47.51% | 13.74B | |
+3.07% | 12.17B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation